Revenue: As of FY2025 Q1, the actual value is USD 373.23 M.EPS: As of FY2025 Q1, the actual value is USD -6.28.EBIT: As of FY2025 Q1, the actual value is USD -43.17 M.<h3>Segment Revenue</h3><ul><li>Capitated Revenue: $369.5 million for the three months ended March 31, 2025, a decrease of $14.6 million, or 4%, compared to $384.1 million for the three months ended March 31, 2024.</li><li>Other Patient Service Revenue: $3.7 million for the three months ended March 31, 2025, a decrease of $0.6 million, or 15%, compared to $4.4 million for the three months ended March 31, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $44.2 million for the three months ended March 31, 2025, compared to - $49.6 million for the three months ended March 31, 2024.</li><li>Operating Loss: - $38.1 million for the three months ended March 31, 2025, compared to - $43.8 million for the three months ended March 31, 2024.</li><li>Gross Profit: $1.2 million for the three months ended March 31, 2025, compared to $6.4 million for the three months ended March 31, 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $33.5 million for the three months ended March 31, 2025, compared to - $20.0 million for the three months ended March 31, 2024.</li><li>Net Cash Provided by Financing Activities: $30.7 million for the three months ended March 31, 2025, compared to $11.4 million for the three months ended March 31, 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Medical Margin: $17.2 million for the three months ended March 31, 2025, compared to $36.6 million for the three months ended March 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue growing its Medicare Advantage membership through existing contracts and new market expansions. It aims to improve health outcomes and profitability by enhancing its care model and expanding its physician network.</li><li>Non-Core Business: The company is exploring raising additional capital through debt financing and equity issuances, and plans to complete the sale of its remaining Florida operations.</li></ul>

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 373.23 M